Evercore ISI Keeps Their Buy Rating on CVS Health (CVS)

Business Insider

26-05-2025

In a report released on May 23, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on CVS Health (CVS – Research Report), with a price target of $85.00. The company's shares closed last Friday at $60.83.
Confident Investing Starts Here:
Anderson CFA covers the Healthcare sector, focusing on stocks such as CVS Health, Align Tech, and Icon. According to TipRanks, Anderson CFA has an average return of -7.8% and a 40.00% success rate on recommended stocks.
CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $80.13, implying a 31.73% upside from current levels. In a report released on May 19, Leerink Partners also reiterated a Buy rating on the stock with a $83.00 price target.
Based on CVS Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $94.59 billion and a net profit of $1.78 billion. In comparison, last year the company earned a revenue of $88.44 billion and had a net profit of $1.11 billion
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVS in relation to earlier this year. Most recently, in March 2025, James David Clark, the SVP, Cont & Chief Acct Officer of CVS sold 7,513.00 shares for a total of $498,487.55.